Join us as our panel discusses the components of a successful ICER evaluation strategy and what pharma manufacturers can do now to prepare. Our panelists bring years of expertise from three different perspectives of the ICER evaluation process: a manufacturer, a consultant, and a former ICER executive. Topics include trends and lessons learned from ICER evaluations today, the growing acceptance of RWE by ICER and its impact on manufacturers, and much more.
Anusha Kheir, MPH, Head US HTA Policy, Strategy and Engagement, Amgen
Dan Ollendorf, PhD, Director of Value Measurement and Global Health Initiatives at the Center for the Evaluation of Value and Risk in Health (CEVR)
Matt Sussman, MA, VP of Modeling & Strategy Services, Panalgo
Patti Peeples, RPH, PhD, President, HealthEconomics.Com, VP Evidence & Content, Scientist.com